Caffeine for Prevention of Alzheimer’s Disease: Is the A<sub>2A</sub> Adenosine Receptor Its Target?
Alzheimer’s disease (AD) is the most prevalent kind of dementia with roughly 135 million cases expected in the world by 2050. Unfortunately, current medications for the treatment of AD can only relieve symptoms but they do not act as disease-modifying agents that can stop the course of AD. Caffeine...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/13/6/967 |
| _version_ | 1797595823377219584 |
|---|---|
| author | Stefania Merighi Alessia Travagli Manuela Nigro Silvia Pasquini Martina Cappello Chiara Contri Katia Varani Fabrizio Vincenzi Pier Andrea Borea Stefania Gessi |
| author_facet | Stefania Merighi Alessia Travagli Manuela Nigro Silvia Pasquini Martina Cappello Chiara Contri Katia Varani Fabrizio Vincenzi Pier Andrea Borea Stefania Gessi |
| author_sort | Stefania Merighi |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) is the most prevalent kind of dementia with roughly 135 million cases expected in the world by 2050. Unfortunately, current medications for the treatment of AD can only relieve symptoms but they do not act as disease-modifying agents that can stop the course of AD. Caffeine is one of the most widely used drugs in the world today, and a number of clinical studies suggest that drinking coffee may be good for health, especially in the fight against neurodegenerative conditions such as AD. Experimental works conducted “in vivo” and “in vitro” provide intriguing evidence that caffeine exerts its neuroprotective effects by antagonistically binding to A<sub>2A</sub> receptors (A<sub>2A</sub>Rs), a subset of GPCRs that are triggered by the endogenous nucleoside adenosine. This review provides a summary of the scientific data supporting the critical role that A<sub>2A</sub>Rs play in memory loss and cognitive decline, as well as the evidence supporting the protective benefits against neurodegeneration that may be attained by caffeine’s antagonistic action on these receptors. They are a novel and fascinating target for regulating and enhancing synaptic activity, achieving symptomatic and potentially disease-modifying effects, and protecting against neurodegeneration. |
| first_indexed | 2024-03-11T02:41:56Z |
| format | Article |
| id | doaj.art-8f63eea7aa66499fbebfefcebf0b871e |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-11T02:41:56Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-8f63eea7aa66499fbebfefcebf0b871e2023-11-18T09:31:19ZengMDPI AGBiomolecules2218-273X2023-06-0113696710.3390/biom13060967Caffeine for Prevention of Alzheimer’s Disease: Is the A<sub>2A</sub> Adenosine Receptor Its Target?Stefania Merighi0Alessia Travagli1Manuela Nigro2Silvia Pasquini3Martina Cappello4Chiara Contri5Katia Varani6Fabrizio Vincenzi7Pier Andrea Borea8Stefania Gessi9Department of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, ItalyDepartment of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, ItalyDepartment of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, ItalyDepartment of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, ItalyDepartment of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, ItalyDepartment of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, ItalyDepartment of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, ItalyDepartment of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, ItalyUniversity of Ferrara, 44121 Ferrara, ItalyDepartment of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, ItalyAlzheimer’s disease (AD) is the most prevalent kind of dementia with roughly 135 million cases expected in the world by 2050. Unfortunately, current medications for the treatment of AD can only relieve symptoms but they do not act as disease-modifying agents that can stop the course of AD. Caffeine is one of the most widely used drugs in the world today, and a number of clinical studies suggest that drinking coffee may be good for health, especially in the fight against neurodegenerative conditions such as AD. Experimental works conducted “in vivo” and “in vitro” provide intriguing evidence that caffeine exerts its neuroprotective effects by antagonistically binding to A<sub>2A</sub> receptors (A<sub>2A</sub>Rs), a subset of GPCRs that are triggered by the endogenous nucleoside adenosine. This review provides a summary of the scientific data supporting the critical role that A<sub>2A</sub>Rs play in memory loss and cognitive decline, as well as the evidence supporting the protective benefits against neurodegeneration that may be attained by caffeine’s antagonistic action on these receptors. They are a novel and fascinating target for regulating and enhancing synaptic activity, achieving symptomatic and potentially disease-modifying effects, and protecting against neurodegeneration.https://www.mdpi.com/2218-273X/13/6/967A<sub>2A</sub> adenosine receptorAlzheimer’s diseaseamyloid betacaffeineneuroinflammationtherapeutic target |
| spellingShingle | Stefania Merighi Alessia Travagli Manuela Nigro Silvia Pasquini Martina Cappello Chiara Contri Katia Varani Fabrizio Vincenzi Pier Andrea Borea Stefania Gessi Caffeine for Prevention of Alzheimer’s Disease: Is the A<sub>2A</sub> Adenosine Receptor Its Target? Biomolecules A<sub>2A</sub> adenosine receptor Alzheimer’s disease amyloid beta caffeine neuroinflammation therapeutic target |
| title | Caffeine for Prevention of Alzheimer’s Disease: Is the A<sub>2A</sub> Adenosine Receptor Its Target? |
| title_full | Caffeine for Prevention of Alzheimer’s Disease: Is the A<sub>2A</sub> Adenosine Receptor Its Target? |
| title_fullStr | Caffeine for Prevention of Alzheimer’s Disease: Is the A<sub>2A</sub> Adenosine Receptor Its Target? |
| title_full_unstemmed | Caffeine for Prevention of Alzheimer’s Disease: Is the A<sub>2A</sub> Adenosine Receptor Its Target? |
| title_short | Caffeine for Prevention of Alzheimer’s Disease: Is the A<sub>2A</sub> Adenosine Receptor Its Target? |
| title_sort | caffeine for prevention of alzheimer s disease is the a sub 2a sub adenosine receptor its target |
| topic | A<sub>2A</sub> adenosine receptor Alzheimer’s disease amyloid beta caffeine neuroinflammation therapeutic target |
| url | https://www.mdpi.com/2218-273X/13/6/967 |
| work_keys_str_mv | AT stefaniamerighi caffeineforpreventionofalzheimersdiseaseistheasub2asubadenosinereceptoritstarget AT alessiatravagli caffeineforpreventionofalzheimersdiseaseistheasub2asubadenosinereceptoritstarget AT manuelanigro caffeineforpreventionofalzheimersdiseaseistheasub2asubadenosinereceptoritstarget AT silviapasquini caffeineforpreventionofalzheimersdiseaseistheasub2asubadenosinereceptoritstarget AT martinacappello caffeineforpreventionofalzheimersdiseaseistheasub2asubadenosinereceptoritstarget AT chiaracontri caffeineforpreventionofalzheimersdiseaseistheasub2asubadenosinereceptoritstarget AT katiavarani caffeineforpreventionofalzheimersdiseaseistheasub2asubadenosinereceptoritstarget AT fabriziovincenzi caffeineforpreventionofalzheimersdiseaseistheasub2asubadenosinereceptoritstarget AT pierandreaborea caffeineforpreventionofalzheimersdiseaseistheasub2asubadenosinereceptoritstarget AT stefaniagessi caffeineforpreventionofalzheimersdiseaseistheasub2asubadenosinereceptoritstarget |